ANDROGEN DEPRIVATION THERAPY USING FINASTERIDE AND LOW DOSE FLUTAMIDE TO TREAT PSA FAILURE FOLLOWING THERAPY FOR CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE (CaP)

Lisle, Turner C.; Mackenzie, Scott H.; Ziada, Ali; Harding, Pamela; Rosenblum, Mark; Stenner, Juan Ignacio; Moul, Judd W.; Crawford, E. David

doi:10.1097/00005392-199904020-00200

Cited by 13 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moul [10] reported on a larger series of men who had early disease progression with PSA-only recurrence. In the most recent report [24], 73 men who had previously been treated with radical prostatectomy or external beam radiation and had PSA recurrence (mean 7.0 ng/ml) were treated with 10 mg finasteride and 250 mg flutamide daily. The mean PSA nadir was 1.35 ng/ml, and the average time to reach the nadir was 6 months.…”

Section: General Treatment Considerations For Early Versus Delayed Homentioning

confidence: 99%

Early versus Deferred Hormonal Treatment for Asymptomatic Prostate Cancer

Mickisch¹

2001

Oncol Res Treat

View full text Add to dashboard Cite

There are two different clinical scenarios in which a decision on hormonal therapy either initially after diagnosis of deferred until the occurrence of signs and symptoms for presently asymptomatic prostate cancer is needed: A more recently described cohort of men with prostate cancer who underwent definitive therapy for putatively curable disease experiencing a rising PSA (biochemical relapse / progression), and a more classical group of men with prostate cancer who were unwilling or unfit to undergo local therapy with curative intent. Long-term hormonal treatment will expose patients to the risk of substantial adverse side effects such as muscle wasting, chronic fatigue, osteoporosis and others, in addition to an overall increase in treatment costs. On the other hand, a potential prolongation of survival and a delay in the development of clinical symptoms may serve as arguments for early treatment. A number of studies have been conducted in which early hormonal treatment delays the time to progression and reduces the cancer-related complication rate such as urinary obstruction and bone fractures. However, results on overall survival remain inconclusive and quality-of-life issues will become more and more important in light of the extended life span of patients with asymptomatic prostate cancer in recent years. Ongoing clinical trials such as EORTC 30991 are needed to provide further information on this important issue.

show abstract

Section: General Treatment Considerations For Early Versus Delayed Homentioning

confidence: 99%

Early versus Deferred Hormonal Treatment for Asymptomatic Prostate Cancer

Mickisch¹

2001

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…In preliminary clinical studies in advanced prostatic cancer, the combination of ®nasteride with either¯ut-amide [12,30] or bicalutamide [6] has been been reported to markedly reduce circulating levels of prostatic speci®c antigen (PSA), thus con®rming the rationale for this novel approach of peripheral androgen deprivation. Further, this type of combined therapy was well tolerated, particularly in maintaining sexual function in most men, unlike the standard treatment with LHRH analogs, which causes loss of libido and potency as a consequence of the decrease in circulating T to castration levels.…”

Section: Discussionmentioning

confidence: 99%

Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide

Zaccheo

Giudici

Panzeri

et al. 2000

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Although finasteride alone (10 mg/d) has been reported to delay serum PSA progression in men with biochemical recurrence after radical prostatectomy; this was short-lived [58]. In an attempt to enhance the impact of finasteride on serum PSA recurrence, the addition of the antiandrogen flutamide has been studied and the results have shown that the combination of these agents appears to have an additive effect [59,60]. Despite this, the long-term effect on disease progression and survival is unknown and, although these agents appear to be better tolerated than LH-RH analogues, breast tenderness, breast enlargement, and nipple tenderness are common [53].…”

Section: Newer Hormonal Therapymentioning

confidence: 99%

“…Despite this, the long-term effect on disease progression and survival is unknown and, although these agents appear to be better tolerated than LH-RH analogues, breast tenderness, breast enlargement, and nipple tenderness are common [53]. Furthermore, gastrointestinal disturbance has been noted in 18% of patients and elevated liver function tests in 9% of patients [60].…”

Section: Newer Hormonal Therapymentioning

confidence: 99%